Biotech Business Advises on Clinical Collaboration Agreement with AstraZeneca

Biotech Business Advises on Clinical Collaboration Agreement with Roche/Genentech

September - 2018

Biotech Business’s client, Biothera Pharmaceuticals Inc., Eagan MN (www.biothera.com) announced today a clinical collaboration with AstraZeneca that will evaluate Biothera’s innate immune modulator, Imprime PGG, in combination with AstraZeneca’s checkpoint inhibitor, durvalumab, in a Phase 2 neoadjuvant study in patients with squamous cell carcinoma of the head and neck.

For more information see :
https://www.biothera.com/biothera-pharmaceuticals-announces-immuno-oncology-clinical-trial-collaboration-with-astrazeneca/

Comments are closed.